Rybelsus (Oral Semaglutide): What It Is, Trial History and Regulatory Status

Evidence tier: Established (FDA-approved; multiple randomized controlled trials).

Rybelsus is a prescription tablet manufactured by Novo Nordisk whose active ingredient is semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. It is the oral formulation of the same molecule marketed as an injection under other brand names. This page summarises what the published literature and regulatory labelling describe about the molecule and the product; it is for educational purposes only and is not medical advice; consult a licensed physician or your prescriber about any medication.

What Rybelsus Is

Active ingredient and drug class

The active ingredient in Rybelsus is semaglutide, an acylated analogue of human GLP-1. A review of the discovery and development of liraglutide and semaglutide described how structural modification of the native GLP-1 peptide — including amino-acid substitution and attachment of a fatty-acid side chain that promotes albumin binding — was used to slow degradation and extend circulating duration relative to native GLP-1 (PMID 31031702). A 2024 systematic review of semaglutide pharmacokinetics reported a terminal half-life of roughly one week for the molecule, which is the property that allows once-weekly injectable dosing (PMID 38952487).

How the mechanism is described in the literature

GLP-1 receptor agonists act at receptors in the pancreas, gastrointestinal tract and central nervous system. The development review described glucose-dependent insulin secretion and suppression of glucagon as core pharmacological actions of this class (PMID 31031702). A 2020 rodent study reported that semaglutide lowered body weight through distributed neural pathways rather than a single hypothalamic site, with researchers mapping effects across several brain regions involved in food intake (PMID 32213703). In humans, a randomised crossover trial in adults with obesity reported reduced ad libitum energy intake, lower appetite ratings, improved self-reported control of eating and reduced body weight after 12 weeks of once-weekly subcutaneous semaglutide escalated to 1.0 mg (PMID 28266779).

The oral formulation

Peptides are normally broken down in the stomach and absorbed poorly, which is why most GLP-1 receptor agonists are injected. Rybelsus is co-formulated with the absorption enhancer sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC), which creates local conditions in the stomach that permit some semaglutide to cross into the circulation. The 2024 pharmacokinetic systematic review reported that oral semaglutide bioavailability is low and variable and that absorption is influenced by concomitant fluid and food intake (PMID 38952487). For that reason, the FDA-approved label specifies particular administration conditions and tablet strengths; those specifics belong to the label and to a prescriber's instructions, and this page does not restate them as guidance.

Approved indications and approval timeline

The FDA approved Rybelsus in September 2019 as the first orally administered GLP-1 receptor agonist, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Marketing authorisation in the European Union followed in 2020. The label has been updated since initial approval, including expansion into cardiovascular risk reduction in defined populations with type 2 diabetes; because indication wording, contraindications and warnings change over time, the current FDA prescribing information and a prescriber remain the authoritative sources. Rybelsus is not approved as a weight-management product in the United States.

Trial History: What the Published Literature Reports

The phase 3 programme of oral semaglutide trials supported the 2019 approval of Rybelsus, and the FDA label remains the authoritative record of those individual trial designs and endpoints. The studies summarised below are drawn from the verified literature set for this page and concern semaglutide as a molecule; unless stated otherwise, they used the subcutaneous formulation, and results from injectable regimens should not be read as results for the oral tablet.

Glycemic trials of semaglutide

SUSTAIN FORTE, a double-blind randomised phase 3B trial, compared two once-weekly subcutaneous doses in adults with type 2 diabetes. The study randomised participants to semaglutide 2.0 mg or 1.0 mg once weekly over 40 weeks, and researchers reported a greater reduction in HbA1c with the 2.0 mg dose than with 1.0 mg, with gastrointestinal adverse events the most frequently reported category in both groups (PMID 34293304). That trial is relevant to Rybelsus mainly as evidence about the molecule's dose–response behaviour in type 2 diabetes rather than about the tablet itself.

Body-weight trials of semaglutide

A systematic review and meta-analysis of randomised trials in obesity without diabetes reported that semaglutide produced significantly greater weight reduction than placebo, alongside a higher rate of gastrointestinal adverse events (PMID 36578889). A narrative review of semaglutide for the treatment of obesity summarised the same body of phase 3 evidence and placed it in cardiometabolic context (PMID 34942372).

STEP 6, a randomised, double-blind, double-dummy, placebo-controlled phase 3a trial in an east Asian population, tested once-weekly subcutaneous semaglutide 2.4 mg and 1.7 mg in adults with overweight or obesity, with or without type 2 diabetes, over 68 weeks, and the study reported greater body-weight reduction with both active doses than with placebo (PMID 35131037). A 2024 analysis of the SELECT trial reported that weight reduction with once-weekly subcutaneous semaglutide 2.4 mg in adults with overweight or obesity and established cardiovascular disease, without diabetes, was sustained over multiple years of continued treatment (PMID 38740993). A review of Wegovy described the approval of once-weekly subcutaneous semaglutide 2.4 mg for chronic weight management in 2021 (PMID 34706925).

Mechanistic and appetite studies

Alongside the large outcome and weight trials, smaller mechanistic work has been published. Researchers in the crossover appetite trial reported lower energy intake at ad libitum meals and reduced hunger ratings during once-weekly subcutaneous semaglutide escalated to 1.0 mg compared with placebo (PMID 28266779), and the rodent neuroanatomy study reported that weight loss persisted when individual candidate brain regions were targeted, suggesting redundancy across pathways (PMID 32213703).

Adverse Events: What Studies Report

Gastrointestinal effects

Across the semaglutide literature, gastrointestinal events dominate the adverse-event tables. A dedicated safety review of semaglutide reported that nausea, vomiting, diarrhoea and constipation were the most commonly reported adverse events, that they were generally mild to moderate and dose-related, and that they accounted for most treatment discontinuations in the trial programme (PMID 34305810). The obesity meta-analysis likewise reported a higher incidence of gastrointestinal adverse events with semaglutide than with placebo (PMID 36578889). In the head-to-head dose comparison, researchers reported that gastrointestinal events were the most frequent adverse events with both once-weekly 2.0 mg and 1.0 mg regimens (PMID 34293304).

Pancreatic, gallbladder and other reported events

The safety review also discussed less common concerns raised in the semaglutide programme and in the GLP-1 class more broadly, including acute pancreatitis, gallbladder-related events, injection-site reactions with subcutaneous formulations, heart-rate increases and hypoglycaemia when the drug was combined with insulin or sulfonylureas (PMID 34305810). The approved labelling for semaglutide products lists warnings in these areas, together with contraindications and guidance on monitoring, and those label sections are the appropriate reference for an individual patient discussion.

Diabetic retinopathy

Retinopathy has been examined specifically because rapid glucose lowering can transiently worsen pre-existing diabetic eye disease. A 2022 meta-analysis pooled randomised controlled trials of semaglutide in type 2 diabetes to assess diabetic retinopathy event rates across the programme (PMID 34894326). Readers with existing retinopathy, and their clinicians, generally consider ophthalmological monitoring as part of any treatment discussion; that assessment is a clinical judgement, not something this page can make.

Regulatory Status and Label Facts

Approvals

Rybelsus is an FDA-approved prescription medicine, first authorised in 2019, and is authorised in the European Union and numerous other jurisdictions. It is dispensed by prescription only. Approved semaglutide products are manufactured and labelled by Novo Nordisk under the brand names Rybelsus, Ozempic and Wegovy.

Boxed warning

Semaglutide products, including Rybelsus, carry a boxed warning in US labelling concerning the risk of thyroid C-cell tumours, based on findings in rodents; the labelling states that it is unknown whether the drug causes medullary thyroid carcinoma in humans and contraindicates use in patients with a personal or family history of medullary thyroid carcinoma or with multiple endocrine neoplasia syndrome type 2. The safety review of semaglutide discussed the thyroid signal among the class concerns evaluated in the clinical programme (PMID 34305810). The full boxed warning text and contraindications appear in the current FDA prescribing information.

Shortages and compounded semaglutide

Injectable semaglutide products appeared on the FDA drug shortage list during periods of intense demand, and the FDA subsequently declared the semaglutide injection shortage resolved in 2025. Under US law, shortage listing is one of the conditions that had permitted certain compounding of a drug that is otherwise commercially available. The FDA has stated that it does not approve compounded drugs and that compounded semaglutide products are not reviewed for safety, effectiveness or quality before marketing. Rybelsus is a tablet manufactured under FDA-approved conditions; it is not a compounded product, and the published trials summarised on this page studied manufactured semaglutide. Nothing here is legal advice.

How Rybelsus Differs From Other Semaglutide Products

All three branded products share one active ingredient but differ in route, dosing frequency, dose range and approved use. The table below summarises those distinctions as reported in the literature and in labelling.

Because the strengths and units differ between the tablet and the injections, milligram figures are not interchangeable across products. Which product, if any, fits a given clinical situation is a prescribing decision.

What the Evidence Does and Does Not Establish

The semaglutide evidence base is unusually large for a metabolic drug: randomised trials in type 2 diabetes, randomised trials in obesity without diabetes, meta-analyses and long-term follow-up analyses. Researchers have reported consistent glycemic and body-weight effects for the molecule (PMID 34293304, PMID 36578889, PMID 38740993). What that literature does not do is tell any individual whether a semaglutide product is appropriate for them, how their comorbidities and other medications interact with it, or what monitoring they need. Trial populations were selected by entry criteria, doses were escalated under protocol, and adverse-event rates were measured in those specific settings (PMID 34305810).

Talking With a Prescriber

Discussion points that recur in the published safety literature include personal or family history of thyroid cancer, prior pancreatitis, gallbladder disease, existing diabetic retinopathy, concurrent insulin or sulfonylurea use, pregnancy planning, and how gastrointestinal tolerability is handled during dose escalation (PMID 34305810, PMID 34894326). Any decision to start, change or stop this medication rests with a reader and their licensed prescriber, informed by the current label.

PeptideU is not affiliated with or endorsed by Novo Nordisk. Rybelsus is a trademark of its owner. This page is for educational purposes only and is not medical advice; consult a licensed physician or your prescriber about any medication.

References

• The Discovery and Development of Liraglutide and Semaglutide (Frontiers in Endocrinology, 2019)
• Clinical Pharmacokinetics of Semaglutide: A Systematic Review (Drug Design, Development and Therapy, 2024)
• Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial (The Lancet Diabetes & Endocrinology, 2021)
• Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial (The Lancet Diabetes & Endocrinology, 2022)
• Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial (Nature Medicine, 2024)
• Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis (Journal of the ASEAN Federation of Endocrine Societies, 2022)
• Semaglutide for the treatment of obesity (Trends in Cardiovascular Medicine, 2023)
• Wegovy (semaglutide): a new weight loss drug for chronic weight management (Journal of Investigative Medicine, 2022)
• Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity (Diabetes, Obesity & Metabolism, 2017)
• Semaglutide lowers body weight in rodents via distributed neural pathways (JCI Insight, 2020)
• Safety of Semaglutide (Frontiers in Endocrinology, 2021)
• Semaglutide and Diabetic Retinopathy Risk in Patients with Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials (Clinical Drug Investigation, 2022)